AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01170585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02849028 — intervention group
Intervention type: BEHAVIORAL
Intervention: sleep disorder
Description: The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
Study NCT03563222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.
Study NCT03563222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid, 20%
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.
Study NCT04554043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study NCT03809390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal seeding
Description: The same as that stated in arm descriptions.
Study NCT03736967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC) every 2 weeks (q2w)
Study NCT03736967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administered SC q2w
Study NCT03736967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500 + Dupilumab Combo
Description: Administered SC q2w
Study NCT03736967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC q2w
Study NCT01030146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NeilMed® Sinus Rinse™ System with Isotonic Saline
Description: NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
Study NCT02841696 — intervention group
Intervention type: DEVICE
Intervention: Cardiac echography
Description: The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
Study NCT04500808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 1
Description: Participants will receive Dose 1 of macitentan tablet in Part 1.
Study NCT04500808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 2
Description: Participants will receive Dose 2 of macitentan tablet in Part 1.
Study NCT04500808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Dose 3
Description: Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
Study NCT04500808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo from Day 1 up to Day 13.
Study NCT00208364 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle Acetabular Cup System
Description: A cementless acetabular cup with metal liner for use in total hip replacement
Study NCT04320498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prp injection
Description: PRP was injected locally in the anal fissure area and glyceryl trinitrate was administered twice daily in the perianal region as in the control group.
Study NCT04320498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrecta
Description: self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
Study NCT04320498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anrecta
Description: self-administered topical glyceryl trinitrate (anrecta), in the perianal area twice a day
Study NCT04320498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sitz bath
Description: participants were told to take a hot water sitz bath once a day
Study NCT04320498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sitz bath
Description: participants were told to take a hot water sitz bath once a day
Study NCT04320498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutrition regulation
Description: The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
Study NCT04320498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrition regulation
Description: The study participants were told to eat a fiber-rich diet and to drink least 2 liters of water daily
Study NCT01403662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
Study NCT00176046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viscum album pini
Description: s.c. injection of 0,001-20 mg 3 times per week
Study NCT00176046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viscum album pini
Description: s.c. injection 0,001-20 mg 3 times per week
Study NCT03191799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
Study NCT03387605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: ivabradine or placebo given orally 2 times daily for 72 hours
Study NCT03387605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo given 2 times daily for 72 hours
Study NCT04204005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.
Study NCT04204005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.~Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.
Study NCT04345003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoma elastography
Description: The standard pre-therapeutic assessment includes a pelvic US to eliminate the presence of calcification of fibroids. If this absence is confirmed, the elasticity of uterine myoma (by ARFI method) will be measured.~The standard pre-therapeutic MRI performed allows to classify and measure the myoma in order to determine if it is accessible for HIFU treatment. MRI elastography sequence with the Resoundant® system will be performed during this exam.
Study NCT02669875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serelaxin
Description: Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
Study NCT02669875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
Study NCT01227369 — intervention group
Intervention type: OTHER
Intervention: OPSAT-Q
Description: A linguistically validated Korean version of OPSAT-Q
Study NCT02755753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
Study NCT01148147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
Study NCT02755753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
Study NCT01148147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracoronary Placebo administration
Study NCT01986075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted behavior therapy
Description: TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
Study NCT01986075 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-assisted behavior therapy
Description: TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
Study NCT01986075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed-Amphetamine Salts- Extended Release (MAS-ER)
Description: 80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
Study NCT01986075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
Study NCT00587626 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive InterX 5000
Description: Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
Study NCT00587626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterX 5000 Treatment
Description: Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
Study NCT03347890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo
Description: Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
Study NCT03347890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo
Description: Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
Study NCT01728311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1082439
Description: BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
Study NCT02755753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
Study NCT02755753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebamipide-placebo
Description: Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
Study NCT03795129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepLife Application w/FitBit
Description: Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application.
Study NCT03795129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FitBit w/Minimal to No SleepLife App.
Description: Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data.
Study NCT02112708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational-Emotive-Behavioral Therapy
Description: A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
Study NCT02112708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group usual care
Description: In the control group the dysthymia is treated as usual with the conventional treatment.
Study NCT04184843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iWalk Toolkit
Description: Intervention period: 5 months~Intervention:~1. A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~2. Access to a clinical expert by email or phone
Study NCT04013087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral feeding of Feihe Stage 1 infant formula
Description: Oral feeding of Feihe Stage 1 infant formula for 16 weeks
Study NCT04013087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral feeding of control Stage 1 formula
Description: Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
Study NCT04013087 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breast feeding
Description: Breast feeding of human milk for 16 weeks
Study NCT02739555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal destruction with radiofrequency or laser
Study NCT02739555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acide Zoledronique
Study NCT01253070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT01253070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate
Study NCT01253070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01253070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT01253070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01253070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01253070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01253070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT03654521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fetal interventricular septum thickness
Description: Two-dimensional ultrasound fetal cardiac imaging test
Study NCT03767140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
Study NCT03767140 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
Study NCT01974401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supragingival irrigators containing chlorhexidine
Description: patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
Study NCT03694132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: conditioning brain activity with peripheral stimulations
Study NCT03694132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: structural MRI
Description: diffusion MRI and tractography for evaluating the brain structures
Study NCT03694132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG/MEG
Description: conditioning brain activity with peripheral stimulations
Study NCT01242800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: palliative surgery
Description: Undergo standard palliative surgery
Study NCT01242800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo early surgery
Study NCT02791256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT02791256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Study NCT02104440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro
Study NCT04267497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Liposomal 50 MG
Description: Amphotericin B 50 mg powder for infusion diluted in 12 ml of sterile water. It will be administered by nebulized route 25 mg (6 ml), 3 times a week, for 6 weeks.
Study NCT04267497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water for injection. It will be administered by nebulized route: 6 ml, 3 times a week for 6 weeks.
Study NCT00716612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q 10
Description: PO Coenzyme Q 10 120 mg QD
Study NCT00716612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: po Placebo QD
Study NCT02064036 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgical Boost
Description: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
Study NCT02064036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex
Description: Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Study NCT02064036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Study NCT03244488 — intervention group
Intervention type: DRUG
Intervention: Scopolamine Injectable Product
Description: 2.5 or 5 mcg/kg of scopolamine via IV
Study NCT03244488 — intervention group
Intervention type: DRUG
Intervention: Mecamylamine Pill
Description: 10 or 20mg of mecamylamine orally
Study NCT04998708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation technique
Description: The intervention group performed two types of relaxation techniques, that have shown their positive effects on immune functions, including progressive muscle relaxation exercise (PMRs)16 and cognitive-behavioral stress management (CBSM)32. We used two types of relaxation techniques to produce maximum effects of relaxation techniques within the limited period of COVID-19 quarantine (2 weeks). the control groups did not receive any treatment during the study; however, they were treated afterwards.
Study NCT03060473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1 gm PO once